NovoSeven RT 2016 U.S. PROMOTIONAL AUDIT REPORT

Published July 2017 • 21 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by NovoSeven RT through personal promotion in 2016 and how does this compare to its peer set in the Glanzmann’s Thrombasthenia and Hemophilia markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Novo Nordisk’s depth of coverage vary within key specialties (e.g., Pediatric Medicine, Hematology/Oncology, and Internal Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for NovoSeven RT throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most detailed prescribers and top paid speakers for NovoSeven RT in 2016?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 42 months of longitudinal data is available – covering payments to more than 900,000 U.S. healthcare professionals.
• Over 300 paid interactions across 200 physicians made on behalf of NovoSeven RT were carefully examined to support our analysis. In addition, interaction data from 12 peer products (e.g. Advate, Adynovate, Afstyla, Alphanate, Alprolix, BeneFix, Eloctate, Kogenate, Kovaltry, Novoeight, Obizur, and Xyntha Solofuse ) was leveraged to provide benchmarking and market insights.